GeneDx Holdings Corp. · NASDAQ:WGS
GeneDx — Q3 2026 Earnings Presentation
39 slides from GeneDx's earnings presentation, Nov 9, 2026
Slide 1: GeneDx Q3 2026 Earnings Presentation
GeneDx Nasdaq: WGS Q3 2026 Earnings Presentation November 2026 Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our mark
Slide 3: Q3 2026 Results
3 Q3 2026 Results Metric Third Quarter 2026 Revenue $123.1 million Exome and genome volume 32,134 Exome and genome revenue $110.4 million Adjusted gross margin1 72% Adjusted net income1 $8.6 million Cash on hand $171.1 million 1 Adjusted gross margin and adjusted net income are non-GAAP financial me
Slide 4: Delivering strong volume growth while improving reimbursement
4 Delivering strong volume growth while improving reimbursement Exome and genome volume year-over-year: • Q3 2026 reported volume up 25% YoY to 32,134 • Accession volume growth up 28% YoY, indicating strong demand 32,134 Q1 2025 Exome and Genome Volume Q2 2025 Q3 2025 Q4 2025 Q1 2026 0 5,000 10,000
Slide 5: Revenue growth stepped up driven by mix shift and RCM performance
5 Revenue growth stepped up driven by mix shift and RCM performance $110.4 Q1 2025 Exome and Genome Revenue (in $M) Q2 2025 Q3 2025 Q4 2025 Q1 2026 0 $20 $98.9 Q3 2024 Q4 2024 $60.0 Exome and genome revenue year-over-year: • Q3 2026 up $10M sequentially and 12% YoY • Q3 ARR up 5% sequentially to ~$3
Slide 6: We've organized the company around three key imperatives
6 We've organized the company around three key imperatives Optimize unit economics Deliver the leading products at unmatched scale Grow utilization of exome and genome
Slide 7: 2026 Guidance Update
7 2026 Guidance Update Metric Full Year 2026 Previous Guidance August 3, 2026 Full Year 2026 Updated Guidance November 9, 2026 Fourth Quarter of 2026 Guidance November 9, 2026 Revenue $475 to $490 million $475 to $490 million $135 million Exome and genome volume At least 30% growth At least 28% grow
Slide 8: Appendix
Appendix —=_ Genel:
Slide 9: Empowering everyone to live their healthiest life through genomics
9 Empowering everyone to live their healthiest life through genomics
Slide 10: GeneDx is the global leader in rare disease diagnosis
10 GeneDx is the global leader in rare disease diagnosis The largest and most diverse rare disease dataset to deliver highest accuracy Diagnosing more rare disease patients than anyone else and delivering 500+ new gene-disease discoveries over 25 years Preferred by 80% of geneticists and granted FDA
Slide 11: An accurate genetic diagnosis is key to transforming healthcare
11 An accurate genetic diagnosis is key to transforming healthcare Enabling precision genomic medicine Providing an early and accurate genetic diagnosis Fueling drug discovery
Slide 12: Delivering the future of precision medicine via the network effect
12 Delivering the future of precision medicine via the network effect Biopharma Accelerating drug discovery, enabling clinical trials, and unlocking biomarkers for targeted therapies with real-world evidence Policymakers Improving population health outcomes with support for evidence-based policies d
Slide 13: Trusted by the nation's leading health systems
13 Trusted by the nation’s leading health systems
Slide 14: GeneDx Infinity is the largest and most diverse rare disease dataset
14 >2.5M >50% >8M ~1M >8M >60% genetic tests non-European descent health records exomes & genomes phenotypic datapoints have parental data GeneDx InfinityTM is the largest and most diverse rare disease dataset Greatest scale advantage Fastest diagnosis and most efficient operations Most comprehensiv
Slide 15: Our AI strategy accelerates the flywheel effect of our data
15 Our AI strategy accelerates the flywheel effect of our data Additional patients tested Improved interpretation platform Higher diagnostic yields and more answers More underlying data N A T U R A L L A N G U A G E P R O C E S S I N G M A C H I N E L E A R N I N G L A R G E L A N G U A G E M O D E
Slide 16: Upside Opportunities
16 Upside Opportunities International, Biopharma/Data, Precision Medicine Pediatrics & Rare Pediatric Specialists, Pediatricians, NICU, Prenatal, and gNBS Adult Adult Neurologists, Adult Cardiologists, and Other Specialists $25B $20B This large and ever-growing opportunity is ours to win
Slide 17: On average, an accurate diagnosis takes years
17 On average, an accurate diagnosis takes 5 years GeneDx provides answers in months weeks days hours First symptom Visit primary care physician Referral to a specialist Genetic testing (CMA) No diagnosis Online research Another specialist Wrong treatment or undue surgery Genetic testing (panel) Inc
Slide 18: Focused on four operational levers to improve blended average reimbursement rates
18 Focused on four operational levers to improve blended average reimbursement rates Manage Mix Expand Payer Coverage Invest In Technology Implement Payer-Specific Workflows1 3 2 4
Slide 19: Monitoring key metrics that translate to higher blended ARR
19 We are monitoring key metrics that translate to higher blended ARR over time Payer Policy CoverageProduct Mix Commercial Covered Lives Genome Q3 outpatient genome mix 98% 90% 88% 47% Exome Q1 Q3 Q1 Q3 Q3 outpatient genome volume submitted to payers with an active positive coverage policy Collecti
Slide 20: Medicaid programs across the country are expanding access
20 Medicaid programs across the country are expanding access 1. GeneDx Internal Data, data on file 2026 Exome Coverage Only Genome Coverage Only Exome and Genome Coverage No Coverage Current Medicaid Coverage Landscape New or Enhanced Coverage
Slide 21: Our north star is to diagnose as many people as fast as possible
21 Our north star is to diagnose as many people as fast as possible
Slide 22: Our stacked, compounding growth strategy unlocks new opportunities
22 Our stacked, compounding growth strategy unlocks new opportunities Foundational Markets (Launched) Expansion Markets (Ramping) Future Markets (Developing) • Geneticists (since inception) • Pediatric Specialists (since 2023) • General Pediatricians (H2 2026) • NICU (since 2024) • Prenatal (H2 2026
Slide 23: Diversifying call points unlocks our total addressable market
23 Diversifying call points unlocks our total addressable market and brings the power of genomic testing to every patient that can benefit 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Geneticsits Pediatric Specialists Prenatal NICU Adult specialists General Pediatrics Clinician Penetration by Market
Slide 24: Entering new markets to deliver answers at the earliest moment possible
24 GeneticistPrenatal Standard of care: years of disease progression Pediatrician Entering new markets to deliver answers at the earliest moment possible NICU Adult Specialist Pediatric Specialist
Slide 25: Geneticists remain key customers and prefer GeneDx
25 Geneticists remain key customers and prefer GeneDx Geneticist recommendations reinforce our leadership in new markets Leading position: 80% market share driven by superior accuracy, broad access, and cutting-edge discovery Continued growth: Largest contributor to revenue today with room to grow v
Slide 26: Pediatric specialists continue to drive high growth
26 Pediatric specialists continue to drive high growth Significant share: Over 30% of pediatric neurologists now order from us with continued growth ahead Strong awareness: Greatest brand recognition of any genetics lab - over 80% of pediatric specialists know GeneDx Expanding our footprint: Continu
Slide 27: Pediatricians are becoming the new front line of genomic medicine
27 Pediatricians are becoming the new front line of genomic medicine Massive market: 600K patients diagnosed with DD/ID by 25K pediatricians annually First mover to an untapped market with the #1 genetic test in hand Trusted partner & clear leader: Leading product, wraparound services, expert endors
Slide 28: The NICU is an untapped opportunity for early intervention
28 The NICU is an untapped opportunity for early intervention and improved outcomes Taking a protocol-driven approach to benefit more patients and lower healthcare costs Large unmet need: Up to 60% of NICU patients could benefit from rWGS per SeqFirst (~235k patients) but less than 5% of them receiv
Slide 29: GenomeDx Prenatal extends our diagnostic capabilities into prenatal care
29 GenomeDx Prenatal extends our industry-leading diagnostic capabilities into prenatal care Setting a new standard for prenatal genomic diagnoses Large unmet need: For patients with structural anomalies on prenatal ultrasound, impacting up to 4% of pregnancies Extensive prenatal experience: Buildin
Slide 30: Adult specialists will unlock future growth and impact
30 Adult specialists will unlock future growth and impact Putting commercial focus behind the organic growth in adult exome and genome testing New market: Expanding to neurologists in 2026 with a focus on clinicians already ordering genetic testing Green space: Strong demand and reimbursement for ad
Slide 31: Global reach with decentralized testing powered by GeneDx Infinity
31 Global reach with decentralized testing powered by centralized intelligence from GeneDx InfinityTM Cloud-native platform enables remote interpretation while complying with local regulations Providing leading interpretation services to key domestic partners Expanded international footprint with sa
Slide 32: Transforming healthcare from diagnostic odyssey to day one action with gNBS
32 Transforming healthcare from diagnostic odyssey to day one action with gNBS GeneDx has the evidence, experience, and operational capabilities to lead global adoption • Partnering with first movers to make gNBS a reality o GUARDIAN o BRIDGES-NBS o Sunshine Genetics • Without gNBS, the average age
Slide 33: Pioneering new channels and partnerships
33 Pioneering new channels and partnerships to deliver on the promise of precision genomic medicine Future Market
Slide 34: Unlocking faster HEOR, biopharma innovation, and AI-driven discovery
34 Unlocking faster HEOR, biopharma innovation, and AI-driven discovery Genetic data Electronic health records Patient demographics Claims Prescription Imaging Deploying the most comprehensive, longitudinal dataset for rare disease ever assembled Future Market
Slide 35: Turning insight into biopharma impact
35 Turning insight into biopharma impact
Slide 36: Proven leadership driving high-growth and operational excellence at scale
36 Proven leadership driving high-growth and operational excellence at scale Heidi Chen Chief Legal Officer Linda Genen Chief Medical Officer Jami Biliboaca Chief People Officer Katherine Stueland Chief Executive Officer Kevin Feeley Chief Financial Officer Melanie Duquette Chief Growth Officer Mark
Slide 37: Executing the right strategy to drive durable, long-term growth
37 Executing the right strategy to drive durable, long-term growth Establish genomic testing as the standard, early answer for suspected genetic disease – expanding access, delivering faster and more actionable diagnoses, and leveraging GeneDx Infinity’s learning to continuously strengthen the platf
Slide 38: Our core competitive advantage compounds with every patient we test
38 Our core competitive advantage compounds with every patient we test. We are setting the industry standard, delivering actionable answers for families and sustainable value for shareholders.
Slide 39: Reconciliation of non-GAAP financial measures
39 Reconciliation of non-GAAP financial measures Adjusted gross profit, adjusted gross margin, and adjusted net income (in $ thousands) Three months ended September 30, 2026 September 30, 2025 June 30, 2026 Revenue $ 123,101 $ 116,743 $ 114,440 Cost of services 37,041 32,216 36,202 Gross profit $ 86